论文部分内容阅读
印巴与欧盟的转运仿制药海关执法案引起了欧盟及国际社会对海关对转运货物进行知识产权执法的正当性的争论。2012年欧盟委员会发布《对于过境欧盟的货物特别是药品的知识产权海关执法指南》。经欧盟转运的货物如被欧盟海关当局认定为有进入欧盟市场的风险,而且该类货物在欧盟成员国境内又有权利人可主张知识产权保护的,将被欧盟海关暂时扣留。《转运货物知识产权海关执法指南》对欧盟边境保护制度进一步发展的意义在于:进一步澄清了欧盟知识产权边境执法所适用的海关程序,扩张性地解释了欧盟海关对转运货物执法的标准,强调对转运药物执法的条件,并未与一般转运货物执法条件存在实质性区别,并弥补了欧盟当前对转运货物的边境保护立法的不足。
The transfer of India-Pakistan-EU generic drug enforcement cases have aroused the EU and the international community on the Customs transit goods for the legitimacy of intellectual property law enforcement debate. In 2012, the European Commission released the Guide to Customs Enforcement of IPRs of Goods, Especially Medicines, Transit European Union. If the goods transhipped by the EU are deemed as having the risk of entering the EU market by the EU customs authorities and the obligee has the right to advocate the protection of intellectual property within the EU member states, they will be detained temporarily by the EU Customs. The significance of the Guide on Customs Enforcement of Trans-shipment of Goods by Intellectual Property to the further development of the European Union’s border protection system lies in further clarifying the customs procedures applicable to enforcing the EU’s IPR border and expansively expounding the EU customs standards on the enforcement of transhipment cargoes, The conditions for the transfer of drug law enforcement did not materially differ from the general transit cargo law enforcement conditions and made up for the current lack of EU border protection legislation on the transshipment of goods.